Telomere maintenance via telomerase reactivation is a nearly universal hallmark of cancer
cells which enables replicative immortality. In contrast, telomerase activity is silenced in most …

Simple Summary Cells undergoing malignant transformation must circumvent replicative
senescence and eventual cell death associated with progressive telomere shortening that …

Myeloid cells can restrain antitumor immunity by metabolic pathways, such as the
degradation of l-arginine, whose concentrations are regulated by the arginase 1 (ARG1) …

Immunotherapy treatments harnessing the patient's immune system herald a new era of
personalized medicine, offering hope for curative responses in patients with serious …

Background Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest tumors
owing to its robust desmoplasia, low immunogenicity, and recruitment of cancer-conditioned …

Telomerase is a reverse transcriptase that maintains telomeres length, compensating for the
attrition of chromosomal ends that occurs during each replication cycle. Telomerase is …

Tumors weakly infiltrated by T lymphocytes poorly respond to immunotherapy. We aimed to
unveil malignancy-associated programs regulating T cell entrance, arrest, and activation in …

Abstract Background The CXCR4-CXCL12 axis plays an important role in the chronic
lymphocytic leukemia (CLL)-microenvironment interaction. Overexpression of CXCR4 has …

Adoptive immunotherapy with engineered T cells is at the forefront of cancer treatment. T
cells can be engineered to express T-cell receptors (TCRs) specific for tumor-associated …

The cytogenetic abnormalities and molecular mutations involved in acute myeloid leukemia
(AML) lead to unique treatment challenges. Although adoptive T-cell therapies (ACT) such …